The drug’s Phase 3 results are comparable to those of Trodelvy, a TROP2-targeting ADC marketed by Gilead Sciences as a second-line treatment for HR positive, HER2 negative breast cancer ...
January 15, 2025—NextBioMedical Co., Ltd., which is based in South Korea, announced that it has received investigational device exemption (IDE) approval from the FDA for its RESORB clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback